Fredag 6 December | 21:30:12 Europe / Stockholm

Prenumeration

Kalender

Tid*
2024-08-22 - Kvartalsrapport 2024-Q2
2024-04-25 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2024-04-24 - Årsstämma
2024-03-06 - Bokslutskommuniké 2023
2023-11-17 - Extra Bolagsstämma 2023
2023-08-24 - Kvartalsrapport 2023-Q2
2023-04-21 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2023-04-20 - Årsstämma
2023-03-02 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-04-22 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2022-04-21 - Årsstämma
2022-03-03 - Bokslutskommuniké 2021
2021-08-26 - Kvartalsrapport 2021-Q2
2021-04-16 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2021-04-15 - Årsstämma
2021-03-03 - Bokslutskommuniké 2020
2020-12-02 - Extra Bolagsstämma 2020
2020-08-27 - Kvartalsrapport 2020-Q2
2020-04-09 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2020-04-08 - Årsstämma
2020-02-27 - Bokslutskommuniké 2019
2019-08-28 - Kvartalsrapport 2019-Q2
2019-04-12 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2019-04-11 - Årsstämma
2019-03-12 - Extra Bolagsstämma 2019
2019-02-28 - Bokslutskommuniké 2018
2018-08-29 - Kvartalsrapport 2018-Q2
2018-04-12 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2018-04-11 - Årsstämma
2018-03-02 - Bokslutskommuniké 2017
2017-11-09 - Extra Bolagsstämma 2017
2017-08-29 - Kvartalsrapport 2017-Q2
2017-04-12 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2017-04-11 - Årsstämma
2017-02-28 - Bokslutskommuniké 2016
2016-08-25 - Kvartalsrapport 2016-Q2
2016-04-12 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2016-04-11 - Årsstämma
2016-02-25 - Bokslutskommuniké 2015
2015-08-19 - Kvartalsrapport 2015-Q2
2015-04-10 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2015-04-09 - Årsstämma
2015-02-27 - Bokslutskommuniké 2014
2014-04-23 - Kvartalsrapport 2014-Q1
2014-03-05 - Bokslutskommuniké 2013

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriLäkemedel & Handel
Herantis Pharma är ett bioteknikbolag i klinisk fas som utvecklar sjukdomsmodifierande terapier för Parkinsons sjukdom. Bolagets ledande produkt HER-096 är en liten syntetisk kemisk peptidomimetisk molekyl utvecklad baserat på CDNF-proteinets aktiva plats. HER-096 kombinerar verkningsmekanismen för CDNF med subkutan administrering. Herantis Pharma grundades 2008 och har sitt huvudkontor i Esbo, Finland.
2024-10-08 07:00:00

Herantis Pharma Plc, Press release, 8 October 2024 at 8:00 AM EEST

Herantis Pharma to host R&D webinar on October 23, 2024

Link to the R&D webinar (10:00-11:00 EET/9:00-10:00 CET): https://herantis.videosync.fi/webinar-10-2024

Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease, will host an R&D webinar on Wednesday October 23rd, 2024. Investors, analysts, partners, media and anyone interested in Herantis and our promising HER-096 development program for Parkinson’s disease are invited to join this virtual event.

Agenda for Herantis’ R&D webinar:

1)        Insights into mechanism of action of HER-096

2)        HER-096 preclinical evidence

3)        HER-096 clinical data

4)        Development plan

5)        Herantis as an investment opportunity

6)        Q&A

R&D Webinar Information:

A webinar (in English) will be held Wednesday October 23rd, 2024, at 10:00 EET / 9:00 CET.

Please use the following link to register for this event: https://herantis.videosync.fi/webinar-10-2024

After registering, you will receive a confirmation email containing information about joining the webcast. Questions can be submitted throughout the webcast event. The recording of the webcast will be available on  https://herantis.com/news-events/video-presentations/ following the event.

About HER-096:

HER-096 is an engineered peptidomimetic molecule designed to mimic the activity of CDNF, a protein that promotes cell survival and functional recovery of neurons. HER-096 modulates the Unfolded Protein Response (UPR) pathway, the regulation of which is essential in restoring the cell protein balance (proteostasis) and preventing the processes leading to, e.g., cytotoxic protein aggregation and neuronal cell death in the brain. In addition, HER-096 alleviates inflammation in the affected brain area. Thanks to its multimodal mechanism of action, Herantis’ HER-096 has the potential to stop the progression of Parkinson’s disease and significantly improve patients’ quality of life.

For more information, please contact:

Tone Kvåle, CFO

Tel: +47 915 19576

Email: ir@herantis.com

Certified Advisor:

UB Corporate Finance Ltd

Tel.: +358 9 25 380 225

E-mail: ubcf@unitedbankers.fi

About Herantis Pharma Plc

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The primary aim of the ongoing Phase 1b clinical trial is to show that repeated subcutaneous doses of HER-096 are safe and well-tolerated in patients with Parkinson’s disease. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in healthy volunteers.

Herantis are listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com